Novartis Oncology in China
About Novartis Oncology China
Novartis Oncology delivers a broad range of innovative therapies to improve and extend the lives of cancer patients. These include Glivec®, Zometa®, Femara®, Desferal®, Aredia® and Navoban®. Novartis Oncology has a robust pipeline capitalizing on recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies. We are expecting Exjade®, Tasigna®, and as well as RAD 001 and SOM 230.
Our Focus
- Focus on the company's culture
- business integrity
- customer focus
For more information, visit the Novartis China websites:
Contact Information
If you wish to contact Novartis Oncology China, please use the information listed below:
Address:
13/F, China World Tower 2,
No.1 Jian Guo Men Wai Avenue,
Chao Yang District, Beijing, China
Telephone: 8610-65058833
关于诺华制药肿瘤药品事业部中国团队
诺华制药肿瘤药品事业部致力于研发广博的创新治疗领域，帮助癌症患者有效治疗并延长生命。其产品包括格列卫®，择泰®，弗隆®，得斯芬®，阿可达®，欧必亭®。诺华制药肿瘤药品事业部运用其持续完善的产品线，不断研究分子基因学，药物设计，以及最先进的药品研发技术。我们拥有即将上市中国的重磅产品Exjade® 和Tasigna®，以及正在研发中的 RAD 001 和 SOM 230。
我们的重点
- 注重企业文化
- 遵守职业操守
- 聚焦客户
了解更多信息，请登陆诺华中国网站：
联系方式
地址：中国北京市朝阳区建国门外大街1号国贸大厦二座13层
电话：8610-65058833
PRODUCTS
At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.
CAREERS AT NOVARTIS
Our success depends entirely on the creativity, performance and achievement of our associates at all levels.
RESEARCH INNOVATION
Novartis maintains the most promising oncology drug pipeline in the industry to treat and help people around the world.
STAY CONNECTED TO THE CANCER RESOURCE CENTER
Receive "Oncology in the News" by email weekly.